| Cell line*1 |
Target
of siRNA*2 |
Evaluation
method*3 |
HVJ-E*4 |
R Reagent*5 |
X Reagent*6 |
| Silencing efficiency (%) |
Viable cells
(%) |
Silencing efficiency (%) |
Viable cells
(%) |
Silencing efficiency (%) |
Viable cells (%) |
(Suspension)
Jurkat
U-937
THP-1
HL-60
Raji
K-562 |
Eg5
Eg5
Eg5
Eg5
Cdc2
Cdc2 |
WST-8
WST-8
WST-8
WST-8
RT-PCR
RT-PCR |
81
93
94
63
73
85 |
84
83
100
89
100
98 |
31
4
45
0
12
81 |
91
100
100
100
94
100 |
6
6
3
4
30
52 |
80
100
100
97
100
100 |
(Adherent)
HeLa S3 |
Eg5 |
WST-8 |
80 |
100 |
76 |
100 |
53 |
77 |
*1Jurkat: Human Acute T cell Leukemia; U-937: Human Histiocytic Lymphoma; THP-1: Human Acute Monocytic Leukemia; HL-60: Human Acute Promyelocytic Leukemia; Raji: Human Burkitt’s Lymphoma; K-562: Human Chronic Myelogenous Leukemia; HeLa S3: Human Adenocarcinoma
*2Eg5: Silencer KIF11(Eg5) siRNA(Ambion, Code No.AM4639); Cdc2: Very High Potency Hs_CDC2 siRNA (QIAGEN, Cat. No. 1027273); Negative control #1 siRNA (Ambion, Code No.4611G)
*3WST-8: Cell Count Reagent SF (Nacalai, Code No.07553-44); RT-PCR: TaqMan Gene Expression Master mix (ABI, Cat No.4369016)
*4HVJ-E-mediated delivery was done using a kit (GenomONE-SiTM)
*5Lipofectamine® RNAiMAX Transfection Reagent (Lifetechnologies, No.13778-075)
*6X-tremeGENE siRNA Transfection Reagent (Roche Applied Science, No.4476093) |
